RESEARCH

• Devine, A., Selland, A., Arriola-Montenegro, J., & Maharaj, V. (2025). Failure to screen for monoclonal proteins in patients who undergo bone scintigraphy for suspected cardiac amyloidosis. Amyloid, 1–3. https://doi.org/10.1080/13506129.2025.2573235

• Selland, A., Agakishi, J., Devine, A., Maharaj, V. (2025). Transthyretin Amyloid Cardiomyopathy: Diagnosis and Management (1st ed., vol. 19). CURRENT CARDIOVASCULAR RISK REPORTS. doi: 10.1007/s12170-025-00771-y  

• Meyer, M., Maharaj, V., Nandy, S., Cogswell, R., van Berlo, J. H., Maurer, M. S., Von Wald, L., Roukoz, H. (2024). Personalized Accelerated Physiologic Dual Rate Pacing for Cardiac Amyloidosis. JACC: Case Reports, 29(22).  doi: 10.1016/j.jaccas.2024.102665

Publications

• Murakami,N., Blosser,C.D., Webber,A.B., Gupta,G., Singh,N., Boppana,S., Master,S., Parasuraman, R., Campagnaro, E. L., Java, A., Sprangers, B., Bhasin-Chhabra, B., Lum, E., Khirfan, D., Alexander, P., Molnar, M. Z., Benes, B., Thakur, A. K., Bumma, N., Karam, S., Hultcrantz, M., Bridoux, F., Sanchorawala, V., Leung, N., Landau, H. (2025). Management recommendations for kidney transplantation in patients with plasma cell dyscrasia. Kidney international. PMID: 40738478 doi: 10.1016/j.kint.2025.07.011 

• Karam,S., Kaushal,A., AbuAmer,N., Royal,V., KItchlu,A. (2024).Non-Immunoglobulin Amyloidosis-Mediated Kidney Disease: Emerging Understanding of Underdiagnosed Entities. Advances in Kidney Disease and Health, 31(4), 334-345. doi: 10.1053/j.akdh.2024.02.001 

• Karam,S., Haidous,M., Royal,V., Leung,N.(2023). Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney international, 103(3), 473-484. PMID: 36502873 doi: 10.1016/j.kint.2022.10.028 

• Karam,S., Leung,N. (2020).Rena lInvolvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins. Hematology/oncology clinics of North America, 34(6), 1069-1079. PMID: 33099424 doi: 10.1016/j.hoc.2020.08.002 

Abstracts

• Allam, Krishna; Nasr, Kristina Karim; Evans, Michael David1; Maharaj, Valmiki; Karam, Sabine. Early Progressive CKD in Wild-Type Transthyretin Cardiac Amyloidosis: Prediagnostic Trajectory and Mortality Risk: SA-PO1172. Journal of the American Society of Nephrology 36(10S):10.1681/ASN.2025ks2cqyav, October 2025. | DOI: 10.1681/ASN.2025ks2cqyav

• Gaddiel Ahmed-Robles, Krishna Allam, Rasha El-Rifai, Hani Hassoun, Heather Landau, Naoka Murakami, Sabine Karam; Evolution of care and outcomes of kidney transplantation in plasma cell dyscrasias: A single center experience. Blood 2025; 146 (Supplement 1): 6377. doi: https://doi.org/10.1182/blood-2025-6377

Publications

• Chompoopong, P., Mauermann, M. L., Siddiqi, H., & Peltier, A. (2024). Amyloid neuropathy: from pathophysiology to treatment in light‐chain amyloidosis and hereditary transthyretin amyloidosis. Annals of Neurology, 96(3), 423-440. https://doi.org/10.1002/ana.26978

• Chompoopong, P., Muchtar, E., & Mauermann, M. (2024). Peripheral Neuropathy in AL Amyloidosis: Clinical Presentations and Outcomes of Current Therapies (S21.008). Neurology, 102(7_supplement_1), 3291. https://doi.org/10.1212/WNL.0000000000204791

• Soontrapa, P., Klein, C. J., Dyck, P. J., Berini, S. E., McPhail, E. D., Binder, M., Chompoopong, P., Engelstad, J., & Shouman, K. (2023). Amyloid-like IgM deposition neuropathy with multiple mononeuropathies and generalized neuropathy. Neuromuscular Disorders, 33(5), 391-395. https://doi.org/10.1016/j.nmd.2023.03.003

• Chompoopong, P., & Mauermann, M. L. (2023). Amyloidosis and autonomic failure. Primer on the Autonomic Nervous System, 575-583. https://doi.org/10.1016/B978-0-323-85492-4.00010-8

• Chompoopong, P., Almarwani, B., & Katirji, B. (2021). Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis. Journal of the Neurological Sciences, 422, 117336. https://doi.org/10.1016/j.jns.2021.117336

For a full list of recent publications by faculty, see:

• Sabine Karam, MD (Nephrology)

• Aimee Merino, MD PhD (Hematology)

• Valmiki Maharaj, MD (Cardiovascular)

• Binoy Yohannan, MD (Hematology)

• Nattawat Klomjit, MD (Nephrology)

• Sean Tracy, MD PhD (Hematology)

• Daniel O'Leary, MD (Hematology)

• Markus Meyer, MD (Cardiovascular)

• Rebecca Cogswell, MD (Cardiovascular)

Elevated Rate Pacing of Cardiac Amyloidosis (Sponsored by Medtronic)

The purpose of this study is to evaluate whether increasing the programmed heart rate of a pacemaker to a more physiologic range improves functional capacity, heart failure symptoms, quality of life, and cardiac biomarkers in patients with cardiac amyloidosis. Cardiac amyloidosis may impair the heart’s ability to maintain an appropriate heart rate, contributing to symptoms and reduced exercise tolerance. This study will assess whether heart rate optimization through pacemaker programming improves clinical and functional outcomes. 

Co-PIs:
Markus Meyer, MD
Valmiki Maharaj, MD

Research Coordinator:
Julie Choate, choat031@umn.edu

Questions? Contact us at amyloid-umn@umn.edu.

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

This is a Phase III randomized clinical trial studying treatment for newly diagnosed AL amyloidosis. It compares Daratumumab + Cyclophosphamide + Bortezomib + Dexamethasone (Dara-VCD) followed by autologous stem cell transplant, vs. Dara-VCD chemotherapy alone to see which approach is more effective at reducing disease progression and improving outcomes, including major organ deterioration and survival. 

View on ClinicalTrials.gov

Questions? Contact us at amyloid-umn@umn.edu.

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis (NEXICART-2)

The purpose of this study is to find the best dose of NXC-201 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment. NXC-201 is a cellular therapy made from your own white blood cells called T cells. If you join this study, we will collect some of your T cells and modify (change) them in a lab. This modification will help your T cells find and kill abnormal plasma cells. These genetically changed T cells are called chimeric antigen receptor (CAR) T cells. NXC-201 is a CAR T cell therapy and is given intravenously (by vein). To prepare your body for NXC-201, you will also get fludarabine and cyclophosphamide, which are chemotherapy drugs. After you get NXC-201, you will be in the hospital for at least 10 days.

PI:
Binoy Yohannan, MD

Research Coordinator:
Roni Milgrom, milgr015@umn.edu

View on ClinicalTrials.gov
View on UMN StudyFinder

Questions? Contact us at amyloid-umn@umn.edu.